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Gamma/Signal Transducers and Activators of Transcription
5A Pathway Plays a Key Factor in Adipogenesis
of Human Bone Marrow-Derived Stromal Cells
and 3T3-L1 Preadipocytes
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Adipogenesis is largely dependent on the signal transducers and activators of transcription (STAT) pathway.
However, the molecular mechanism of the STAT pathway in the adipogenesis of human bone marrow-derived
stromal cells (hBMSCs) remains not well understood. The purpose of this research was to characterize the tran-
scriptional regulation involved in expression of STAT5A and STAT5B during adipogenesis in hBMSCs and 3T3-L1
cells. The expression of STAT5A and STAT5B increases with the onset of adipogenesis in hBMSCs and 3T3-L1 cells.
The PPAR response elements regulatory element of STAT5A exists at a promoter region ranging from - 346 to
- 101, and the CCAAT/enhancer-binding protein (C/EBP) regulatory element is located at - 196 to - 118 of the
STAT5B promoter. C/EBPb and C/EBPa bound to the STAT5B promoter region, whereas peroxisome proliferator-
activated receptor g (PPARg) bound to STAT5A. RNA interference of STAT5A completely blocked differentiation,
whereas the inhibition of STAT5B only partially blocked differentiation. We propose that C/EBPa, C/EBPb, and
PPARg control adipogenesis by regulating STAT5B and STAT5A and that STAT5A is necessary, whereas STAT5B
plays a supplementary role during adipogenesis. Further, the regulation of PPARg-STAT5 by C/EBPb signaling
seems to be the crucial adipogenesis pathway-initiating cascade of the various adipogenic genes.
Introduction
Human bone marrow-derived stromal cells (hBMSCs)have the capacity to differentiate into multiple lineages
and the ability for self-renewal. Specifically, BMSCs are well
known for their potential to differentiate into adipocytes, os-
teoblasts, chondrocytes, myocytes, and neurocytes [1–6]. Im-
balances in osteogenic and adipogenic differentiation are
related to aging and diseases. In aging patients or people with
osteoporosis, decreased bone density is observed along with
reduced osteoblast numbers and increased adipocyte num-
bers, which suggest that balanced adipogenesis and osteo-
genesis are important for the maintenance of bone structure
and volume [7–9]. Therefore, a comprehensive understanding
of the complicated network of various transcription factors
and genes involved in the transdifferentiation of hBMSCs into
adipocytes and osteoblasts is crucial for developing and im-
proving the treatment of osteoporosis.
Previous research has shown that adipogenesis is a com-
plex process involving the proliferation of precursor cells,
adipocyte formation, and terminal differentiation [10]. Var-
ious gene cascades and signaling pathways are involved in
the process. CCAAT/enhancer-binding protein (C/EBP)
family members belong to the basic leucine zipper class of
transcription factors and they bind to specific DNA se-
quences as dimers with other C/EBPs. The transcriptional
activity of peroxisome proliferator-activated receptor g
(PPARg) is dependent on both heterodimerization with ret-
inoid X receptor a (RXRa) and the regulation of fatty acid
binding protein 4 (FABP4), leptin, and adiponectin by the
heterodimers [10–15].
The introduction of adipogenic hormonal stimuli activates
2 transcription factors crucial for the initiation of adipogen-
esis, C/EBPb and C/EBPd. They continue to be expressed for
approximately 2 days, and they induce the expression of C/
EBPa and PPARg [10,13,15]. Activated C/EBPa and PPARg
upregulate the expression of one another in a positive feed-
back loop. Simultaneously, C/EBPa and PPARg regulate the
expression of adipocyte genes necessary for the development
of functional, mature adipocytes [11,13–17]. Despite detailed
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knowledge about the molecular pathways involved in adi-
pogenesis, we do not yet have a complete understanding of
the signaling pathways and functional mechanisms behind
each process, and the potential mediators between C/EBPa
and PPARg and terminal differentiation markers have not
been yet identified.
Signal transducers and activators of transcription (STATs)
are a family of latent transcription factors of cytokine-
mediated signaling events in cell growth and differentiation
[18–21]. STAT1–6 comprise a group of latent cytoplasmic
transcription factors that are activated by cytokines, pep-
tides, and growth factors. STAT proteins form homo- or
heterodimers at tyrosine phosphorylation sites, and dimer-
ized STAT proteins immediately enter the nucleus, where
they bind to specific DNA sequences in the promoters of
various genes and mediate transcriptional regulation. STATs
are involved in a variety of cellular processes such as innate
and acquired immunity as well as cell proliferation, mam-
mary cell differentiation, lymphoid development, and cell
survival [20]. Studies have shown increased expression levels
of STAT genes during adipogenesis [22–27], and it has been
reported that ectopic expression of STAT5A in NIH3T3 cells
induces adipogenesis [22]. In primary rat preadipocytes, GH-
mediated inhibition of FABP4 gene expression was shown to
be regulated by activation of the STAT5A signaling pathway
[28]. Collectively, these studies have shown that STATs and
their target genes play a specific role in adipogenesis; how-
ever, the regulators of STAT remain unknown.
In this study, we sought to identify the potential regula-
tors of STAT5A and STAT5B expression with a particular
interest in the transcription factors already shown to display
a distinct expression pattern during adipogenesis. Specifi-
cally, we focused on the transcriptional regulation of STA-
T5A and STAT5B by C/EBPa, C/EBPb, and PPARg and
confirmed the effect of STAT5A and STAT5B on adipogen-
esis using an siRNA silencing technique. We demonstrated
that inhibition of STAT5A expression completely blocks
adipogenesis; however, inhibition of STAT5B only partially
inhibits adipogenesis. Additionally, we demonstrated that
C/EBPa and C/EBPb directly regulate the transcriptional
activity of STAT5B and that PPARg regulates STAT5A.
Materials and Methods
hBMSCs and 3T3-L1 cells cultures
and differentiation
Bone marrow aspirates were obtained from the posterior
iliac crest of 7 healthy volunteers aged 13–69 years after
approval from the institutional review board. hBMSCs were
purified from the marrow using the Percoll density gradient
centrifugation method. hBMSCs were cultured in Dulbecco’s
modified Eagle’s medium (DMEM)-low glucose (Gibco,
Carlsbad, CA) supplemented with 10% fetal bovine serum
(FBS; Welgene, Daegoo, South Korea) and 1% antibiotic–
antimycotic solution; confluence was achieved within 7 days.
The cells were cultured for 14 days in an adipogenic medium
consisting of DMEM-low glucose supplemented with 1%
antibiotic–antimycotic solution plus MDI (0.5mM isobutyl-
methylxanthine, 1mM dexamethasone, and 200 mM indo-
methacin; Sigma, St. Louis, MO) and 5 mM insulin (Sigma).
Next, 3T3-L1 preadipocytes were propagated and main-
tained in DMEM-high glucose (Gibco) containing 10% calf
serum (Gibco). To induce adipogenic differentiation, the cells
were treated with DMEM-high glucose containing 10% FBS,
1mg/mL insulin, 1mMdexamethasone, and 0.5mM 3-isobutyl-
1-methylxanthine until day 2. The cells were then treated
with DMEM supplemented with 10% FBS and 1mg/mL in-
sulin for 2 days and were finally treated every other day with
DMEM containing 10% FBS.
Plasmid constructs
Expression plasmids for pCMV-C/EBPa, pCMV-C/EBPb,
pCMV-PPARg, and pCMV-RXRa were constructed. Expres-
sion plasmids for pcDNA-STAT5A and pcDNA-STAT5B
were gifts from Dr. H. Yamashita (Nagoya City University
Graduate School of Medical Science, Nagoya, Japan). The
mouse STAT5A promoter region spanning - 1500 to + 57 bp
was cloned into the pGL3-basic vector and named pGL-1500.
Constructs pGL-766, pGL-346, and pGL-101 containing 5’
serial deletions of the STAT5A promoter reporter were con-
structed by amplifying the STAT5A promoter regions from
- 766 to + 57, - 346 to + 57, and - 101 to + 57 bp, respec-
tively. The STAT5B promoter region spanning - 1443 to
+45bp was cloned into the pGL3-basic vector and named
pGL-1443. Constructs pGL-600, pGL-196, and pGL-118 con-
taining 5’ serial deletion of the STAT5B promoter reporter
were constructed by amplifying mouse STAT5B promoter re-
gions from - 600 to +45, -196 to + 45, and - 118 to +45bp,
respectively, and subcloning into the pGL3-basic vector.
Transient transfection and luciferase
reporter assays
3T3-L1 and NIH3T3 cells in 6-well plates were cultured in
DMEM supplemented with 10% bovine calf serum (BCS)
(Gibco) , 100U/mL penicillin, and 100 mg/mL streptomycin.
Transient transfections were performed using Lipofectamine
2000 (Invitrogen, Carlsbad, CA) according to the manufac-
turer’s protocol. Briefly, 500 ng of the luciferase reporter
construct, 200 ng of the mouse C/EBPa and mouse C/EBPb
expression vectors, 100 ng of the pCMV-b-galactosidase ex-
pression vector, and 4mL of Lipofectamine 2000 were inde-
pendently mixed with 250mL of opti-MEM and incubated for
5min. To transfect constant amounts of DNA, sample DNAs
were supplemented with the control vector pcDNA3. After
5min of incubation, diluted DNA samples were mixed with
Lipofectamine 2000 and incubated for 20min at room tem-
perature. During this period, the cells were washed twice
with phosphate-buffered saline, and 2mL of opti-MEM was
added. After 20min of incubation, transfection mixtures
were added to the cells and incubated at 37C in 5% CO2 and
95% air for 12 h. Next, the medium was replaced with
DMEM containing 10% BCS (Gibco). After 24 h, the cells
were harvested and lysed with 200 mL of reporter lysis buffer
(Promega, Madison, WI), and cell debris was removed by
centrifugation. Luciferase activities were measured using
20mL of cell extract and 50mL of luciferase assay reagent
(Promega). b-Galactosidase activity was measured for 50mL of
cell extract with 50mL of 2·b-galactosidase assay reagent
containing O-nitrophenyl-b-galactopyranoside. Luciferase ac-
tivities were normalized to b-galactosidase activities to adjust
for transfection efficiency. Lucifease activities from the wild-
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type promoter constructs in the absence of any reporters were
used as controls. The assays were performed in triplicate.
Chromatin immunoprecipitation analysis
Chromatin immunoprecipitation (ChIP) analysis was
performed, as described in the protocol included in the ChIP
assay kit (Upstate Biotechnology, Charlottesville, VA).
Briefly, hBMSCs and 3T3-L1 preadipocytes were maintained
and induced to differentiate as described earlier. At various
time points, the cells were cross-linked with 1% formalde-
hyde in PBS buffer. The cross-linked cells were harvested,
lysed in sodium dodecyl sulfate lysis buffer, and sonicated.
After incubation with salmon sperm DNA/protein A at 4C
overnight, the DNA–protein complexes in the supernatant
were immunoprecipitated with antibodies against C/EBPb,
C/EBPa, and PPARg (Santa Cruz Biotechnology, Santa Cruz,
CA), and the immune complexes were recovered by adding
protein A–agarose. After washing the DNA–protein A
complex with saline, DNA was extracted with phenol/
chloroform, precipitated, redissolved, and used as a template
for polymerase chain reaction (PCR). We used the mouse
STAT5A promoter primers (sense, AAAAGGTTCAGGTTTT
CCCC; and antisense, GGCTTCCTCTCTTACTAAT), the
mouse STAT5B promoter primers (sense, GCTTCAGCCGA
GACCCTTCA; and antisense, GGTCAGCTGCTTCAGAC
AGA), and the human STAT5B promoter primers (sense,
CTCCCTGAACCTACTCTGTG; and antisense, CACTCTCC
TTTCCTCTGCTA).
Nuclear extract preparations and TNT reactions
For nuclear extract preparations, the cells were harvested
in a 10-cm plate. Hypotonic lysis buffer containing 20mM
Tris-Cl (pH 7.5), 10mMNaCl, 3mMMgCl2, 1mMdithiothreitol,
1mM sodium orthovanadate, 30mM b-glycerophosphate,
and 1·PIC I and II. Igepal CA-630 was added to a final
concentration of 0.1%, and the cells were homogenized. The
homogenates were centrifuged at 2,000 rpm for 10min. The
pellet of intact nuclei was resuspended in NUN buffer con-
taining 0.3M NaCl, 1M urea, 1% NP-40, 25mM HEPES (pH
7.6), 1mM dithiothreitol, 1mM sodium orthovanadate,
30mM b-glycerophophate, and 1·PIC I and II and incu-
bated for 30min on ice. The samples were centrifuged at
12,000 rpm at 4C for 10min. Supernatants containing nu-
clear extracts were analyzed for protein content using the
BCA assay kit. To produce PPARg and RXRa protein, we
used the TNT kit (Promega). Reaction mixtures containing
TNT T7 quick master mix, 0.5 mg of DNA template, and 1mM
[35S]methionine were incubated at 30C for 90min.
Electrophoretic mobility shift analysis
Electrophoretic mobility shift analysis (EMSA) was per-
formed using the following method. Reaction mixtures
containing *0.25 ng of the appropriate 32P-labeled oligonu-
cleotide probe, 2mg of poly[d(I-C)], and 10mg of nuclear ex-
tract protein (for C/EBPa and C/EBPb protein) or 2 mL of
TNT mixtures (for PPARg and RXRa protein) in 30 mL of
buffer (10mM HEPES, 100mM NaCl, 0.3M urea, 0.3% NP-
40, 0.1mM EDTA, and 5% glycerol) were incubated on ice
for 15min and then at room temperature for 15min. Proteins
and labeled oligonucleotide probes were separated by elec-
trophoresis on 5% polyacrylamide gels in 0.5 ·TBE. For su-
pershift experiments, 1mL of antiserum was added to the
reaction mixture before the addition of labeled probe. The
labeled oligonucleotide probes included double-stranded
oligonucleotides corresponding to the C/EBP regulatory el-
ement in the STAT5B promoter, (- 153) AATGTGATTGCGT
ACTAGCTGC ( - 132), and a cold probe based on the C/EBP
binding site of the C/EBPa promoter. The PPRE regulatory
element in the STAT5A promoter was used as probe 1, (-301)
CAGCCCAGACATTTTCAACTTCTGC (-277), probe 2,
(-206) AAAGACCAGAAAGAAGGATCAGG (-183), and
probe 3, (-140) CCTCCAGGCCACTGGGTCTTGGCC (-117).
The positive control (CNTL) was the PPRE regulatory element
in the FABP4 promoter, TTTGCCTTCTTACTGGATCAGAG
TTCAC.
RNAi of STAT5A, STAT5B, PPARc, and C/EBPb
Synthetic siRNA oligonucleotides specific for regions in
STAT5A, STAT5B, PPARg, and C/EBPb mRNA were de-
signed and synthesized by Bioneer (Daejeon, South Korea).
The silencing effects of several siRNA oligonucleotides were
first tested for their ability to silence STAT5A, STAT5B,
PPARg, and C/EBPb expression. 3T3-L1 preadipocytes in 6-
cm dishes at 90% confluence were transfected with siRNA
oligonucleotides using Lipofectamine 2000, and the cells
were subjected to the standard differentiation protocol at
24 h later. Finally, cell extracts were prepared for analysis at
various time points. Control transfections were performed
with Negative Control Duplexes (Bioneer).
Oil Red O staining for adipogenesis
Monolayer cultured cells were rinsed with PBS, fixed in a
3.7% solution of formaldehyde buffer for 3min, washed with
distilled water, and stained with an Oil Red O solution for
1 h, followed by repeated washing with 70% ethanol. After
staining, the cells were photographed. Assays were per-
formed in triplicate in at least 3 independent experiments.
Reverse transcription-polymerase chain reaction
Total RNA was isolated from 3T3-L1 cells using the
RNeasy kit (Qiagen, Valencia, CA). The total RNA was
reverse-transcribed using the Omniscript kit (Qiagen); all
experiments were performed with Taq DNA polymerase
(Qiagen). The reaction products were subjected to 1.5%
agarose gel electrophoresis. Reverse transcription-polymerase
chain reaction (RT-PCR) was used for amplification using the
following primers: STAT5A 1F-ATGGGGA CTATGATC
CAGGC, STAT5A 2F-CGTCAGGAGCCGTCA GAAGC,
STAT5A 3R-CCCAGCTTGATCTTCAGCAA, STAT5B 4F-
GAGGACTCAAGACGGTCCCT, STAT5B 5F-T GCGGATG
AGAAAACTGAGG, and STAT5B 6R-AAGTA GTGCCG
GACCTCGAT.
Immunoblotting
Cell extracts were prepared by adding 1·passive lysis
buffer (Promega) and a cocktail of protease and phosphatase
inhibitors (Sigma). Aliquots (20mg) of cell lysates were sep-
arated by 10% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis under reducing conditions. Separated
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proteins were transferred to a PVDF membrane (Amersham
Pharmacia, Piscataway, NJ) at 50V for 2 h in transfer buffer.
Membranes were blocked with 5% skimmed milk dissolved
in 1·TBST buffer at room temperature for 1 h. The mem-
branes were probed with the following primary antibodies:
STAT5A, STAT5B, pSTAT5 (BD, Franklin Lakes, NJ), FABP4,
C/EBPa, C/EBPb, PPARg, and GAPDH (Santa Cruz Bio-
technology). Immunoblots were visualized using the ECL
Plus detection kit (Amersham Pharmacia).
Results
The expression of STAT5 and phosphorylated
STAT5 is induced during hBMSC adipogenesis
We observed the expression of STATs and phosphorylated
STATs during the adipogenesis of hBMSCs. The expression
levels of STAT1, STAT2, and STAT4 decreased in a time-
dependent manner after the induction of adipogenic differ-
entiation, whereas the expression levels of STAT3 and STAT6
did not change during adipogenesis. Interestingly, STAT5
expression increased in a time-dependent manner (Fig. 1A).
Phosphorylated STAT1 (p-STAT1) was expressed until day 1,
p-STAT4 was transiently activated on adipogenesis day 1, and
p-STAT5 was activated in a time-dependent manner. The ex-
pression of p-STAT2 and p-STAT6 was not detected (Fig. 1B).
Using the TESS program, we predicted the presence of a C/EBP
binding site within the STAT5B promoter region. Using ChIP
assays, we detected the binding of C/EBPa to the STAT5B
promoter, which indicated that the transcription of STAT5B
was regulated by C/EBPa during adipogenesis (Fig. 1C).
The expression of STAT5A and STAT5B is induced
during the adipogenesis of 3T3-L1 preadipocytes
hBMSCs have characteristically high heterogeneous phe-
notypes, which makes it extremely difficult to correctly as-
sess the expression of different gene cascades in multiple
donors. Therefore, we used the 3T3-L1 preadipocyte cell line
to examine our hypothesis. During the adipogenesis of 3T3-
L1 preadipocytes, the expression of C/EBPb began to in-
crease at 4 h into differentiation and was maintained for up to
48 h, after which the expression level was noticeably reduced.
The expression of C/EBPa and PPARg increased at 38 h into
differentiation and was followed by expression of the ter-
minal marker gene FABP4 at approximately 72 h (Fig. 2A).
During the adipogenesis of 3T3-L1 preadipocytes, STAT3
expression was maintained throughout the entire period,
whereas STAT 2, STAT4, and STAT6 were not expressed at
all. The only other STAT genes with any significant expres-
sion pattern were STAT1 and STAT5, which showed gradual
increase in expression during adipogenesis (Fig. 2B). Differ-
entiated cells were stained with Oil Red O on day 6 after the
induction of differentiation (Fig. 2C). Using western blot and
RT-PCR, STAT5A and STAT5B were found to be weakly
expressed prior to the onset of adipogenesis, followed by an
initial decrease in expression at early stages of differentiation
and a gradual increase after 38 h (Fig. 2D, E).
C/EBPa and C/EBPb control the expression
of STAT5B, and PPARc and RXRa control
the expression STAT5A
In a previous study, it was shown that STAT5A and
STAT5B have alternative promoters in different cells types
[29,30]. To determine whether STAT5A and STAT5B have at
least 2 promoters in mouse preadipocytes, we analyzed
STAT5A and STAT5B mRNA transcripts using RT-PCR.
Figure 3 shows a map of the STAT5A and STAT5B loci,
which identifies STAT5A promoters 1 (P1) and 2 (P2) and
STAT5B promoters 1 (P1) and 2 (P2), as well as the locations
of primer sets for RT-PCRs to distinguish between the tran-
scripts produced by these promoters. RT-PCR of STAT5A
was analyzed using primer set 1F-3R and 2F-3R, and the
analysis showed that promoter 1 was used to drive the ex-
FIG. 1. The expression of STATs and
phosphorylated STATs during hBMSCs adi-
pogenesis. hBMSCs were induced with
0.5mM isobutyl-methylxanthine, 1 mM
dexamethasone, 200mM indomethacin, and
5 mM insulin in DMEM-LG medium con-
taining 10% FBS for 14 days. The expression
levels of STATs (A) and phosphorylated
STATs (B) were confirmed by western blot.
GAPDH was used as an internal control. (C):
At different times after adipogenesis in-
duction, cells were cross-linked with form-
aldehyde, the DNA was fragmented, and
the chromatin-associated DNA was im-
munoprecipitated with IgG or antibodies
against C/EBPa. PCR amplification of the
DNA fragments was performed with specific
primers flanking the C/EBP regulatory ele-
ment in the STAT5B promoter. STAT, signal
transducers and activators of transcription;
hBMSC, human bone marrow-derived stro-
mal cell; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal
bovine serum; IgG, immunoglobulin; C/EBP, CCAAT/enhancer-binding protein; PCR, polymerase chain reaction.
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pression of STAT5A in 3T3-L1 preadipocytes. RT-PCR of
STAT5B in 3T3-L1 preadipocytes using primer sets 4F-6R
and 5F-6R showed that promoter 1 was used to drive the
expression of STAT5B gene. RT-PCR of STAT5A and
STAT5B in 3T3-L1 preadipocytes during 3T3-L1 adipogen-
esis showed that promoter 1 of STAT5A and STAT5B, re-
spectively, were used to drive gene expression (Fig. 3).
Following the observation that C/EBPa binds to the
STAT5B promoter during adipogenesis of hBMSCs (Fig. 1C),
we examined luciferase assays to verify whether other tran-
scription factors such as C/EBPa, C/EBPb, PPARg, or RXRa
also affect the transcriptional activity of STAT5A and STAT5B
through DNA binding. As shown in Fig. 4A, we observed that
the transcriptional activity of STAT5A was not changed by the
presence of either C/EBPa, C/EBPb, or both C/EBPa and C/
EBPb. However, the transcriptional activity of STAT5B
showed a 2–6 fold increase in the presence of either C/EBPa,
C/EBPb, or both C/EBPa and C/EBPb. Additionally, we
tested the effect of PPARg and RXRa on the transcriptional
activity of STAT5A and STAT5B. As shown in Fig. 4B, PPARg
and RXRa induced a 12-fold increase in STAT5A transcrip-
tional activity. However, they did not induce significant
changes in STAT5B transcriptional activity. Collectively, these
data demonstrate that C/EBPa and C/EBPb induce the
transcriptional activity of STAT5B, and PPARg and RXRa
induce the transcriptional activity of STAT5A.
Identification of the element responsible
for the transcriptional activation induced by C/EBPa,
CEBPb, PPARc, and RXRa at the STAT5A
and STAT5B promoters
To precisely localize the regions in the STAT5A and
STAT5B promoters targeted by C/EBPa, C/EBPb, PPARg,
and RXRa, several truncated STAT5A and STAT5B pro-
moter-luciferase constructs were produced (Fig. 5A, D). We
FIG. 2. The expression of
adipocyte-specific marker
genes during the differentia-
tion of 3T3-L1 preadipocytes.
3T3-L1 preadipocytes were
induced with DMEM-HG
containing 10% FBS, 1mg/mL
insulin, 1 mM dexamethasone,
and 0.5mM 3-isobutyl-1-
methylxanthine until day 2.
The cells were treated with
DMEM supplemented with
10% FBS and 1 mg/mL insulin
for 2 days, and they were then
treated every other day with
DMEM containing 10% FBS.
(A)Analysis ofmarker protein
expression levels by western
blot. 3T3-L1 cells were differ-
entiated into adipocytes and
lysed at each time point, and
total protein was prepared for
immunoblotting with the in-
dicated antibodies. (B) The
expression of STATs during
adipogenesis of 3T3-L1 pre-
adipocyte.3T3-L1preadipocytes
were differentiated into adi-
pocytes using hormonal stim-
uli. STAT expression levels were confirmed by western blot. GAPDH was used as an internal control. (C) Differentiated cells
were stained with Oil Red O on day 6 after differentiation induction. (D, E) The expression of STAT5A and STAT5B during the
differentiation of 3T3-L1 preadipocytes. The expression of STAT5A, STAT5B, and adipocyte marker genes was analyzed at
different time points after the induction of differentiation. 3T3-L1 preadipocytes were differentiated into adipocytes. The
analysis of STAT5A and STAT5B expression levels was confirmed bywestern blot (D) and RT-PCR (E). GAPDHwas used as an
internal control. PPARg, peroxisome proliferator-activated receptor g; FABP4, fatty acid binding protein 4; RT-PRC, reverse
transcription-polymerase chain reaction.
FIG. 3. Analysis of STAT5A and STAT5B
mRNA transcripts by RT-PCR. Map of
STAT5A and STAT5B showing the locations
of primers 1F and 4F (specific for promoter
P1), 2F and 5F (specific for promoter P2), as
well as the reverse primers (3R and 6R) prior
to induction and after differentiation of 3T3-
L1 cells transcripts.
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then examined the elements responsible for C/EBPa, C/
EBPb, PPARg, and RXRa binding to STAT5A and STAT5B
promoters by performing transient transfection assays in
3T3-L1 preadipocytes and NIH3T3 fibroblasts using the re-
spective reporter constructs. The constructs pGL-STAT5A-
1500/+ 57-luc, - 766/ + 57-luc, and - 346/ + 57-luc did not
show any changes in transcriptional activities, whereas the
pGL-STAT5A-101/ + 57-luc construct lost its transcriptional
response to PPARg and RXRa (Fig. 5B, C). pGL-STAT5B-
1433/+ 45-luc, - 600/ + 45-luc, and - 196/ + 45-luc did not
show any changes in the transcriptional response to C/EBPa
and C/EBPb, but pGL-STAT5B-118/ + 43-luc lost its tran-
scriptional response to C/EBPa and C/EBPb (Fig. 5E, F).
Additionally, PPARg, RXRa, C/EBPa, and C/EBPb did not
affect transcriptional activity of the pGL3-basic construct.
As shown in Figs. 4 and 5, C/EBPa and C/EBPb increased
the transcriptional activity of STAT5B, whereas PPARg in-
creased the transcriptional activity of STAT5A. To confirm
the transcriptional relevance of PPARg in regulating STAT5A
expression and the transcriptional relevance of C/EBPa and
C/EBPb in regulating STAT5B expression, 3T3-L1 pre-
adipocytes were induced to undergo adipogenesis and ChIP
analyses were performed. PPARg was bound to the - 346/
- 101 region of the STAT5A promoter on day 3 following the
induction of differentiation (Fig. 6A). C/EBPa bound the
STAT5B promoter in the - 196/ - 118 region on days 1 and 2,
and C/EBPb bound the STAT5B promoter in the - 196/
- 118 region on days 1, 2, and 3 of differentiation (Fig. 6B).
These results indicate that C/EBPa and C/EBPb directly
interact with the STAT5B promoter and increase the tran-
scriptional activity of STAT5B, whereas PPARg directly in-
teracts with the STAT5A promoter and increases the
transcriptional activity of STAT5A.
To confirm the exact sequence of the PPRE binding region
within the STAT5A promoter, we performed a preliminary
test using 3 putative PPRE binding sequences and the pre-
viously identified PPRE binding element of the FABP4 pro-
moter. The PPARg and RXRa TNT mixture combined with an
individual probe showed a noticeable shift in the CNTL
group, and we observed the disappearance of the shifted
band in the presence of competitor. Individual binding of the
probes to PPARg and RXRa occurred only with probes 1 and
2, and PPARg and RXRa showed stronger binding to the
probe 1 element sequence. No significant binding of PPARg
and RXRa was observed for probe 3 (Fig. 6C).
To locate the C/EBP binding site within the STAT5B
promoter, we constructed 2 putative C/EBP sequences.
Following a similar preliminary test, we identified the se-
quence with higher binding efficiency, which was then used
for EMSA. Nuclear extracts from cells that had undergone
adipocyte differentiation for 16 h were used to confirm probe
binding, and the shift assay using both C/EBPa and C/EBPb
antibodies yielded a supershift in nuclear extracts from days
2 and 3. Additionally, when a known competitor, C/EBP
binding sequence, was added, we observed the disappear-
ance of the shifted band in the cold probe group (Fig. 6D).
Based on the results presented in Figs. 5 and 6, the C/EBP
element located at position - 132 is likely to be involved in
C/EBPa- and C/EBPb-mediated activation of the STAT5A
promoter, whereas the PPRE element located at positions
- 194 and - 105 likely functions in PPARg- and RXRa-me-
diated activation of the STAT5A promoter.
C/EBPb is a key regulator of 3T3-L1 differentiation
during adipogenesis
We used luciferase assays and ChIP analysis to determine
that STAT5A is regulated by PPARg and RXRa; however,
STAT5B is regulated by C/EBPa and C/EBPb during the
differentiation of 3T3-L1 preadipocytes. To more specifically
determine the function of C/EBPb and PPARg, 3T3-L1 cells
were transfected with C/EBPb siRNA or PPARg siRNA to
block the expression of C/EBPb or PPARg and the cells were
then induced to differentiate into adipocytes. The cells
transfected with C/EBPb or PPARg siRNA had significantly
lower expression levels of C/EBPb and PPARg compared
with the cells transfected with negative control siRNA.
FIG. 4. The transcriptional activity of STAT5A and STAT5B
by C/EBPa, C/EBPb, PPARg, and RXRa expression. NIH3T3
cells were cotransfected with each of the indicated luciferase
constructs, pGL-STAT5A and pGL-STAT5B, and an over-
expression vector, pCMV-C/EBPa, pCMV-C/EBPb, pCMV-
PPARg, or pCMV-RXRa. (A) Transcriptional activity was
measured from the STAT5A or STAT5B promoter by C/EBPa
and C/EBPb overexpression vectors using luciferase assays.
(B) Transcriptional activity was measured from STAT5A or
STAT5B promoters by PPARg and RXRa. Results are shown
as relative luciferase activities. The assays were repeated in at
least 3 times. Each sample was normalized to the level of b-
galactosidase activity, and asterisk (*) indicates P< 0.05 versus
the mock vector group. RXRa, retinoid X receptor a.
470 JUNG ET AL.
Additionally, C/EBPb siRNA completely blocked differen-
tiation, whereas the inhibition of PPARg only partially
blocked differentiation (Fig. 7A). The cells transfected with
C/EBPb siRNA showed reduced C/EBPb expression as well
as C/EBPa, PPARg, STAT5A, STAT5B, and FABP4 expres-
sion. However, PPARg siRNA inhibited only PPARg, C/
EBPa, and FABP4 expression and did not affect the expres-
sion of C/EBPb or STAT5B (Fig. 7B). PPARg siRNA partially
inhibited the expression of STAT5A.
STAT5 is necessary for 3T3-L1
and hBMSC adipogenesis
To assess the effects of STAT5A and STAT5B on adipo-
genesis, the cells were transfected with STAT5A and STAT5B
overexpression plasmids. When 3T3-L1 preadipocytes were
transfected with either mock, STAT5A, STAT5B, or STAT5A/
STAT5B overexpression plasmids, all 3 overexpression vec-
tors displayed an increased accumulation of lipids compared
with the group treated with mock vector (Fig. 7C). To more
specifically determine the function of STAT5A and STAT5B,
3T3-L1 cells were transfected with STAT5A siRNA and
STAT5B siRNA to block STAT5A and STAT5B expression,
followed by adipogenesis induction. To assess the progress
of adipogenesis, Oil Red O staining was performed on day 6
after transfection with each siRNA. In the scramble group in
which negative siRNA was transfected as a control, we were
able to detect lipid droplet formation, whereas the STAT5A
siRNA-treated group showed a complete lack of lipid
droplets. The STAT5B siRNA-treated group displayed less
lipid droplet formation compared with the control. In the
STAT5A and STAT5B siRNA cotransfected group, lipid
FIG. 5. Localization of the element in the STAT5A and STAT5B promoters responsible for transcriptional activation by C/
EBPa, C/EBPb, PPARg, and RXRa. Schematic representations showing STAT5A promoter-luciferase constructs (A) and
STAT5B promoter-luciferase constructs (D). A luciferase reporter construct, pGL, pGL-1500, pGL-766, pGL-346, or pGL-101
(STAT5A promoter luciferase constructs), was cotransfected with PPARg and RXRa overexpression vectors in 3T3-L1 pre-
adipocytes (B) and NIH3T3 fibroblasts (C). A luciferase reporter construct, pGL, pGL-1443, pGL-600, pGL-196, or pGL-118
(STAT5B promoter luciferase constructs), was cotransfected with C/EBPa and C/EBPb overexpression vectors in 3T3-L1
preadipocytes (E) and NIH3T3 fibroblasts (F). The assays were repeated in at least 3 times. Each sample was normalized to
the level of b-galactosidase activity, and asterisk (*) indicates P < 0.05.
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droplet formation was completely inhibited similar to the
group transfected with STAT5A siRNA alone (Fig. 7D).
Following the confirmation that STAT5A and STAT5B play
crucial roles in adipogenesis, we next asked whether STA-
T5A and STAT5B had similar functions in hBMSCs. In
hBMSC adipogenesis, the inhibition of STAT5A and STAT5B
expression by siRNA also resulted in reduced lipid droplet
formation similar to what was seen for 3T3-L1 preadipocytes
(Fig. 7E).
These data confirm that the importance of STAT5A and
STAT5B during adipogenesis is conserved between 3T3-L1
cells and hBMSCs. Following the inhibition of STAT5A and
STAT5B, we also tested the expression of various marker
genes. In the scrambled group, all of the marker genes, includ-
ing STAT5A, STAT5B, PPARg, C/EBPa, C/EBPb, and FABP4,
were detected,whereas the STAT5A siRNA-transfected group
showed a reduction in PPARg, C/EBPa, and FABP4 expres-
sion. In the STAT5B siRNA-transfected group, STAT5B ex-
pression was inhibited, and FABP4 expression was reduced
compared with the scramble group. When both STAT5A and
STAT5B siRNAswere transfected, the expression of allmarker
genes except C/EBPb was reduced (Fig. 7F). Collectively,
thesedata indicate that thepresence of STAT5AandSTAT5B is
crucial for differentiation; however, STAT5A may act as a
particularly important factor in adipogenesis.
Discussion
Previous studies have shown that STAT expression in-
creases during adipogenesis. In particular, STAT5 expression
increases in both mouse and human adipogenesis, and
overexpression of STAT5A promotes the accumulation of
triglycerides within cells [23,31,32]. However, the exact
mechanism of STAT5A and STAT5B regulation remains
poorly understood. Previous studies have established C/
EBPa, C/EBPb, and PPARg as key regulators of the differ-
entiation of 3T3-L1 preadipocytes during adipogenesis
[10,13,15]. Here, we investigated the transcriptional regula-
tion of STAT5A and STAT5B by C/EBPa, C/EBPb, and
PPARg and examined its roles in adipogenesis. Our studies
demonstrate that (i) C/EBPa and C/EBPb transactivator
activity regulates the expression of STAT5B; (ii) PPARg and
RXRa transactivator activity regulates the expression of
STAT5A; (iii) inhibition of STAT5A blocks adipogenesis; and
(iv) inhibition of STAT5B partially blocks adipogenesis.
In reporter assays, we found that C/EBPa and C/EBPb
activated STAT5B but not STAT5A, whereas PPARg and
RXRa controlled only STAT5A activity. We discovered a
PPRE responsive region spanning bases - 346 to - 101 in the
STAT5A promoter and a C/EBP responsive region spanning
bases - 196 to - 118 in the STAT5B promoter. We identified
3 sites that are similar to the PPRE consensus sequence
(RGGTCANRGGTCA or RGGTCANACTGGR) in the STA-
T5A promoter, but our EMSA analysis indicated that 2 sites
at positions - 301 to - 277 and - 206 to - 183 were bound by
a PPARg and RXRa complex. Also, we identified 2 sites that
were similar to the C/EBP consensus sequence
(RTTGCGYAAY) in the STAT5B promoter, but only 1 site, at
position - 153 to - 132, was bound by the C/EBPa and C/
EBPb nuclear protein complex.
FIG. 6. CEBPa and C/EBPb bind to the STAT5B promoter, and PPARg binds to the STAT5A promoter. At different times
after the induction of differentiation, cells were cross-linked with formaldehyde, the DNA was fragmented, and the chromatin-
associated DNA was immunoprecipitated with IgG or antibodies against C/EBPa, C/EBPb, or PPARg. PCR amplification of
the DNA fragments was performed with specific primers flanking the PPRE regulatory element in the STAT5A promoter (A)
and the C/EBP regulatory element in the STAT5B promoter (B). (C) In vitro translated PPARg and RXRa proteins were tested
by electrophoretic mobility shift analysis with the putative PPRE binding sequence on the STAT5A promoter (probe 1, probe
2, and probe 3). The PPRE regulatory element in the FABP4 promoter was used as a positive control. CNTL sequence was
used to construct the cold probe. (D) Postconfluent 3T3-L1 preadipocytes were induced to differentiate using MDI on day 0.
Nuclear extracts were prepared at various time points after induction. For the supershift assay, 2mg of anti-C/EBPa or anti-
C/EBPb antibody was added into the reaction mixture. C/EBP regulatory element in the C/EBPa promoter was used to
make the cold probe. CNTL, positive control.
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C/EBPb is a well-known initiation factor of adipogenesis
[17], and consequently, C/EBPb siRNA completely inhibited
adipogenesis and the expression of C/EBPa, PPARg, STA-
T5A, STAT5B, and FABP4. PPARg siRNA also inhibited
adipogenesis and the expression of C/EBPa and PPARg, but
it did not have any effect on the expression of C/EBPb. Be-
cause C/EBPb is an initiator and upstream molecule in-
volved in differentiation, the inhibition of PPARg did not
affect the expression of C/EBPb. In the feedback regulation
between PPARg and C/EBPa [33,34], the inhibition of
PPARg reduced C/EBPa expression.
Inhibition of STAT5A expression completely blocked adi-
pocyte differentiation, whereas the inhibition of STAT5B only
partially blocked adipocyte differentiation. Therefore, our re-
sults indicate that the expression of STAT5A is necessary,
whereas the expression of STAT5B is supplementary in adi-
pogenesis. These results support the findings of a previous
study that demonstrated that the overexpression of STAT5A
induces an increase in adipocyte differentiation; however,
overexpression of STAT5B alone does not yield the same ef-
fects in NIH3T3 cells [22]. Additionally, STAT5A and STAT5B
double knock-out mice showed somewhat reduced epidermal
fat pads [35]. In the present study, the inhibition of STAT5A
expression decreased C/EBPa and PPARg expression, but not
C/EBPb expression, and the inhibition of STAT5B expression
did not affect C/EBPa, C/EBPb, or PPARg expression. The
expression of FABP4, a known target gene of PPARg, was also
reduced in the STAT5A siRNA-treated group; however, it was
unaffected by STAT5B siRNA treatment. Based on this result,
one can speculate that PPARg regulates the transcriptional
activity of STAT5A,which in turn regulatesC/EBPaorPPARg
expression. This hypothesis is supported by other studies in-
dicating that dominant STAT5 partially blocks the expression
of C/EBPa, PPARg, and FABP4 during adipogenesis, as
shown via northern blots [36]. It is also supported by the
finding that PPARg promoters can be regulated by STAT5
[37,38]. During angiogenesis, STAT5 transactivator activity
controls PPARg expression. Additionally, heterodimer for-
mation of the STAT5/PPARg transcriptional complex binds to
cyclin D1 and regulates its transcriptional activity [39]. In
summary, STAT5A is regulated by PPARg; however, it also
directly regulates the expression of PPARgvia a feedback loop.
The RNA interference study showed the potential for
STAT5 autoregulation, and we performed luciferase assays
FIG. 7. C/EBPb, PPARg, STA-
T5A, and STAT5B expression is
important during adipogenesis.
(A) C/EBPb RNAi, PPARg RNAi,
or scramble siRNA transfected
cells were stained with Oil Red O
solution on day 6 after differenti-
ation induction. (B) 3T3-L1 cells
were transfected with C/EBPb
RNAi (50 nM), PPARg RNAi
(50 nM), or scramble siRNA
(50 nM) using Lipofectamine 2000.
After transfection, the cells were
induced to differentiate into adi-
pocytes, and C/EBPb and PPARg
knockdown was confirmed by
western blot analysis on day 3. (C)
3T3-L1 preadipocytes were trans-
fected with pcDNA3 empty vector
(mock vector), pcDNA3-STAT5A,
or pcDNA3-STAT5B and induced
to differentiate without post-
confluent incubation for 2 days.
Transfected cells were stained
with Oil Red O on day 6 after
differentiation induction. (D) 3T3-
L1 preadipocytes were transfected
with STAT5A RNAi, STAT5B
RNAi, STAT5A RNAi and
STAT5B RNAi, or scramble siR-
NA and induced to differentiate
without postconfluent incubation
for 2 days. Transfected cells were
stained with Oil Red O solution
on day 6 after differentiation in-
duction. (E) STAT5A RNAi
(50 nM), STAT5B RNAi (50 nM), STAT5A RNAi (50 nM) and STAT5B RNAi (50 nM), or scramble siRNA (50 nM)-transfected
cells were stained with Oil Red O solution on day 14 after hBMSC adipogenesis. (F) 3T3-L1 cells were transfected with
STAT5A RNAi (50 nM), STAT5B RNAi (50 nM), or scramble siRNA (50 nM) using Lipofectamine 2000. After transfection, the
cells were induced into adipocytes, and STAT5A and STAT5B knockdown was confirmed by western blot analysis on day 3.
Additionally, the expression of adipogenic marker genes was confirmed by western blot analysis. GAPDH was used as an
internal control.
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to verify this possibility. The results indicated that STAT5B
cannot be autoregulated by STAT5A or STAT5B; how-
ever, STAT5A may be autoregulated by either STAT5A or
STAT5B (data not shown). These results suggest that STA-
T5A is initially activated by PPARg during the early stages of
adipogenesis. However, its expression may switch to auto-
regulation afterward. Consequently, the inhibition of PPARg
caused only a slight reduction of STAT5A expression, which
further supports the idea that STAT5A expression was
maintained and enforced by autoregulation, despite the ini-
tial absence of PPARg.
Conclusion
C/EBPa and C/EBPb bound to the STAT5B promoter,
whereas PPARg bound to the STAT5A promoter. We
showed that C/EBPa and C/EBPb directly regulate the
transcriptional activity of STAT5B, and PPARg regulates the
transcriptional activity of STAT5A. In RNA interference ex-
periments, the expression of STAT5A was required, whereas
the expression of STAT5B was supplementary to adipogen-
esis. These data indicate that STAT5A plays a major role in
adipogenesis and STAT5B has only a supportive function.
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